| 2020-08 |
BPR6K609: An Aurora kinase inhibitor targeting small cell lung cancer with MYC amplification |
Cancer Research. 2020 Aug;80(16):1937. |
|
| 2019-10 |
Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117) |
Annals of Oncology. 2019 Oct;30(Suppl. 5):191. |
 |
| 2019-07 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 227. |
|
| 2019-07 |
Use of integrated genomic analyses in patient-derived tumor model to discover new clinical indications for the multikinase inhibitor drug candidate, DBPR216 |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 4626. |
|
| 2019-07 |
An Aurora kinase inhibitor BPR6K471 inhibits tumor growth and reduces the cancer stem cell-like properties of small cell lung cancer |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 3851. |
|
| 2018-12 |
Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer |
Cancer Science. 2018 Dec;109(SI, Suppl. 2):210. |
|
| 2018-12 |
Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer |
Cancer Science. 2018 Dec;109(Suppl. 2, SI):1257. |
|
| 2018-07 |
4-Bromophenylhydrazinyl benzenesulfonylphenylureas inhibit indoleamine 2,3-dioxygenase in vitro and in vivo |
Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 1664. |
|
| 2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer |
Cancer Science. 2018 Jan;109(Suppl. 1):739. |
|
| 2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation |
Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482. |
|
| 2016-12 |
Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P. |
|
| 2016-10 |
Multifunctional nanoparticles for oral protein drug delivery |
Diabetes Research and Clinical Practice. 2016 Oct;120(Suppl. 1):S19. |
|
| 2016-08 |
Dipeptidyl peptidase-4 inhibitor LAF-237 improves glucose tolerance and expends graft beta cell mass in diabetic mice transplanted with a sufficient number of islets |
Diabetologia. 2016 Aug;59(Suppl. 1):S198. |
|
| 2016-02 |
Multifunctional nanoparticles for oral protein drug delivery |
Nanomedicine: Nanotechnology, Biology and Medicine. 2016 Feb;12(2):463. |
|
| 2015-08 |
Zinc-dipicolylamine directed pharmaceutical delivery system (ZAPS) as an innovative cancer drug delivery platform |
Cancer Research. 2015 Aug;75(Suppl. 15):Abstract number 4413. |
|
| 2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia |
Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490. |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
|
| 2014-10 |
YYEI motif is critical to oncogenicity of 14-3-3 proteins |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 3527. |
|
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI. |
|
| 2013-11 |
A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780. |
|
| 2013-04-07 |
BPR000K, a novel Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI. |
|
| 2013-04-07 |
Development drug candidate targeting EGFR kinase: DBPR112 |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI. |
|
| 2013-04 |
Design and synthesis of Aurora kinase inhibitors as anticancer agents |
Abstracts of Papers - American Chemical Society. 2013 Apr;245:Article number 301-MEDI. |
|
| 2012-11 |
BPR1J271, a novel FLT3 inhibitor for treating acute myeloid leukemia |
European Journal of Cancer. 2012 Nov;48(Suppl. 6):53-54. |
|
| 2012-06 |
Involvement of transcriptional regulator Ndt80 in stress responses of Candida albicans |
Mycoses. 2012 Jun;55(Suppl. S4):131-132. |
|
| 2011-09 |
Effects of dipeptidyl peptidase 4 inhibition with MK-0431 on syngeneic mouse islet transplantation |
Diabetologia. 2011 Sep;54(Suppl. 1):S181. |
|
| 2011-05 |
Study of glioblastoma multiforme metastatic and invasive mechanism by polycistronic imaging probe in tumor implanted animal model |
Journal of Nuclear Medicine. 2011 May;52(Suppl. 1):Meeting Abstract 1709. |
|
| 2011-03-27 |
Design and synthesis of potent Aurora kinase inhibitors |
Abstracts of Papers - American Chemical Society. 2011 Mar 27;241:258-MEDI. |
|
| 2010-08 |
Lead optimization of furanopyrimidine Aurora kinase inhibitors: Development of in vivo active agents in tumor xenograft models |
Abstracts of Papers - American Chemical Society. 2010 Aug;240:MEDI 332. |
|
| 2006-09 |
MEDI 416-3- 2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino -3-methyl-butyr amide analogs as DPP-IV inhibitors for the treatment of type-II diabetes |
Abstracts of Papers - American Chemical Society. 2006 Sep;232:MEDI 416. |
|
| 2005-03 |
Design and structure-activity relationships of novel indole-based PPAR agonists as antidiabetic agents |
Abstracts of Papers of the American Chemical Society. 2005 Mar;229(Part 2):U141. |
|
| 2005-03 |
Design, synthesis and sar of indole-based PPAR agonists |
Abstracts of Papers of the American Chemical Society. 2005 Mar;229(Part 2):U141. |
|
| 2004-09 |
Drug design of BPR0L075 as an anticancer agent |
World Conference on Magic Bullets - Celebrating Paul Ehrlich's 150th Birthday. 2004 Sep 9-11:Abstract # 203. |
|
| 2004-07 |
Drug design for BPR0L075 as an anticancer agent |
Medicine in the 21st Century Tri-Conference & Bio-Forum 2004 Shanghai International Convention Center. 2004 Jul. |
|
| 2004 |
Acellular biological tissues loaded with a novel angiogenic agent (ginsenoside Rg1) as a tissue-engineering extracellular matrix |
Transactions - 7th World Biomaterials Congress. 2004:1725. |
|
| 2002-03 |
Sympathoinhibitory action of nociceptin in the rat spinal cord |
Clinical and Experimental Pharmacology and Physiology. 2002 Mar;29(3):233-237. |
|
